Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study
Authors:
- Elice Carneiro BatistaEBElice Carneiro Batista
- Diogo Diniz Gomes BuganoDBDiogo Diniz Gomes Bugano
- Rodrigo Guimarães CorradiRCRodrigo Guimarães Corradi
- Renato PanhocaRPRenato Panhoca
- João Antonio SolerJSJoão Antonio Soler
- Andréa Lopes Ponte de SouzaASAndréa Lopes Ponte de Souza
- Bruna MotkeBMBruna Motke
- Henrique Alkalay HelberHHHenrique Alkalay Helber
- Bruna dos Santos SampaioBSBruna dos Santos Sampaio
- Frederico MonfardiniFMFrederico Monfardini
- 1 April 2026
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (4) , e2500324
Abstract
PURPOSE: Disparities in health care access and resource availability in middle-income countries often lead to suboptimal management of localized bladder urothelial carcinoma (UC). However, real-world data describing treatment patterns and outcomes in these settings remain limited. METHODS: This multicenter, retrospective, real-world study included patients with high-risk non–muscle-invasive (HR-NMIBC) and localized muscle-invasive bladder cancer (MIBC) diagnosed between 2017 and 2022 across nine cancer centers in a middle-income setting. Treatment data and clinical outcomes were collected from medical records and analyzed using descriptive statistics and Kaplan-Meier survival estimates. RESULTS: Among 343 patients analyzed, 217 (63.3%) had HR-NMIBC, of whom only 29.5% received adjuvant Bacillus Calmette-Guérin (BCG), often substituted with intravesical gemcitabine because of supply shortages. BCG exposure was associated with superior overall and cancer-specific survival compared with non-BCG patients. In the muscle-invasive cohort (n = 126; 36.7%), cystectomy was performed in 48.4% and significantly improved survival. Perioperative chemotherapy remained limited, with only 39.3% receiving neoadjuvant therapy, and just one third receiving cisplatin-based regimens that conferred the greatest survival benefit. CONCLUSION: This multicenter real-world study exposes major gaps in the management of localized UC in a middle-income setting. Limited access to BCG, perioperative chemotherapy, and cystectomy remain key barriers to guideline-concordant care, underscoring the urgent need for policy actions to improve treatment delivery and outcomes in comparable health care systems.Keywords
This publication has 36 references indexed in Scilit:
- EBANO study: real-world data from patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in Northern SpainESMO Real World Data and Digital Oncology, 2024
- Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-GuérinEuropean Urology Oncology, 2022
- Real-World Evidence and Real-World Data for Evaluating Drug Safety and EffectivenessJAMA, 2018
- Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysisCancer Epidemiology, 2013
- Epidemiology and Risk Factors of Urothelial Bladder CancerEuropean Urology, 2013
- Who should be included in a clinical trial of screening for bladder cancer?Cancer, 2012
- Smoking Status Is a Risk Factor for Recurrence After Transurethral Resection of Non–Muscle-Invasive Bladder CancerEuropean Urology, 2011
- Chemoprevention of bladder cancerWorld Journal of Urology, 2006
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006